Leading the Way in Life Science Technologies

GEN Exclusives

More »

March 15, Vol. 31, No. 6

  • Feature Articles

    • GEN's 30th Anniversary: Antisense
    • Recent news stories have noted that RNAi technology, once thought so promising among many in the life science community and especially big pharma, is now falling out of favor The biggest hit took place last November when Roche dropped out ... more »
    • Cancer Marker Pursuit Heats Up
    • K. John Morrow Jr.
    • The search for cancer biomarkers has proven to be a long, frustrating, and mainly fruitless exercise Despite the substantial investment, no new markers suitable for large-scale screening protocols have achieved FDA approval Yet, improvements in investigative tools, as well as ... more »
    • Status of Cell and Gene Therapy Keeps Vacillatin...
    • Vicki Glaser
    • At Phacilitate’s recent “Cell & Gene Therapy Forum”, enthusiasm greeted reported advances in the research laboratory and successes in the commercial arena for technologies that represent high-risk ventures for the companies developing them Excitement also accompanied the introduction of pioneering ... more »
    • Tracking Predictive ADME/Tox Advances
    • John Russell
    • Cell imaging is an increasingly useful tool in predictive ADME/Tox strategies, according to Karen Tilmant, PhD, research scientist, investigative nonclinical safety, at UCB Pharma, who spoke at Mondial Research Group’s “Conference on Predictive Human Toxicity and ADME/Tox Studies” held recently ... more »
    • miRNA Drugs Close In on Clinical Debut
    • Kathy Liszewski
    • MicroRNAs (miRNAs) are master regulators involved in multiple physiological and pathological processes These naturally occurring, noncoding, single-stranded RNAs (21–25 nucleotides long) base-pair with their target mRNA within the RISC (RNA-induced silencing complex) The latter is the same ribonucleoprotein machinery associated ... more »
    • Zooming In on Single-Cell Analysis
    • Kate Marusina
    • The analysis of individual cells is now a reality Single-cell signatures may tell us a lot about the tissue microenvironment, differentiation, aging, or regeneration For instance, tumor microenvironment contains multiple cell types including immune cells, stroma, cells of blood vessels, ... more »
    • PAT Slowly Yielding to Broader QbD
    • Angelo DePalma
    • Nearly eight years after the US FDA’s landmark guidance on process analytic technology (PAT), implementation remains slow and uneven, leading some to ask when this initiative will achieve the broad improvements originally promised... more »
    • Expression Systems Break with Tradition
    • Gail Dutton
    • The challenge to produce more protein faster is leading to the development of new, engineered cell hosts and more tightly targeted ways of introducing genetic material to those hosts, as well as strategies that exert more precise control even at ... more »
  • Columns

    • NIH Pharma Co. Is a Bad Idea
    • Henry I. Miller, M.D.
    • Because of concerns within the Obama administration about the glacial pace of new drugs coming out of the pharmaceutical industry’s pipeline, the feds have announced a billion-dollar government drug development center to help create new medicines It’s typical government-think: Having ... more »
    • Semantics Integration Tools Free Up Data
    • Carol Potera
    • Making sense of complex genomic and proteomic data is becoming easier as a result of advances in bioinformatics Imagine connecting data in a fraction of the previously required time, and also incorporating information from published scientific papers, patient responses to ... more »